FIELD: chemistry.SUBSTANCE: present invention relates to compounds of formula (I), pharmaceutically acceptable salts or stereoisomers thereof, method for production and use thereof in medicine:where A is phenyl , or thienyl, where phenyl is substituted with 1–5 halogen atoms and -OR7; R7 is C1-6 alkyl, where C1-6 alkyl is optionally substituted by one or more groups selected from a deuterium, halogen, C1-6 alkoxy and C1-6 cycloalkoxy; or said phenyl substituted only with -OR7, where R7 is C1-6 alkyl, and said C1-6 alkyl is additionally substituted with 1–3 groups selected from halogen and C3-10 cycloalkoxy; or, if A represents or thienyl, thienyl is possibly substituted with one or more groups selected from halogen, C1-6 alkyl and phenyl, optionally substituted with deuterium or a halogen; R1, R2, R3 or R4 are selected from hydrogen, C1-6 alkyl or halogen; R5 and R6 are selected from hydrogen and deuterium. Disclosed method of producing a compound of formula (I) involves conversion of compound of formula (IA) into a compound of formula (IB)removal of protection from compound of formula (IB) to obtain a compound of formula (I); where R1-R6 and A are defined above, X and Y are protective hydroxyl groups.EFFECT: disclosed are novelsodium-dependent glucose cotransporter (SGLT)-1 inhibitors and an efficient method for preparation thereof.16 cl, 13 ex, 2 tblНастоящее изобретение относится к соединениям формулы (I), их фармацевтически приемлемым солям или стереоизомерам, способу их получения и применению в медицине:где А представляет собой фенил, , или тиенил, где фенил замещен 1-5 атомами галогена и -OR7; R7 представляет собой C1-6 алкил, где C1-6 алкил возможно замещен одной или более группами, выбранными из дейтерия, галогена, C1-6 алкокси и C1-6 циклоалкокси; или указанный фенил замещен только -OR7, где R7 представляет собой C1-6 алкил, и указанный C1-6 алкил дополнительно замещен 1-3 группами, выбранными из галогена и С3-10 циклоалкокси; или, если А представляет соб